Inhibitors of Aurora kinases for the treatment of cancer

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 9, 2005, Pages 1169-1182

  Fancelli, Daniele ^a   Moll, Jürgen ^a  

^a NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

Aurora kinase; Cancer treatment; Inhibitor; Mitosis

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AURORA A KINASE ANTIBODY; AURORA KINASE; AURORA KINASE INHIBITOR; AZD 1152; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; HESPERIDIN; INDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PHA 680632; PROTEIN KINASE; PROTEIN KINASE SYK INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRAZOLONE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2;

BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CANCER THERAPY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG DESIGN; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME LOCALIZATION; HELA CELL; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; LEIOMYOSARCOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

EID: 25444509584     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.9.1169     Document Type: Review

References (39)

1. GUMIREDDY K, REDDY MV, COSENZA SC et al.: ON0 1910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell (2005) 7(3):275-286.
2. MAYER TU, KAPOOR TM, HAGGARTY SJ, KING RW, SCHREIBER SL, MITCHISON TJ: Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science (1999) 286(5441):971-974.
3. KEEN N, TAYLOR S: Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer (2004) 4(12):927-936.
4. MARUMOTO T, ZHANG D, SAYA H: Aurora-A - a guardian of poles. Nat. Rev. Cancer (2005) 5(1):42-50.
5. MONTEMBAULT E, PRIGENT C: Aurora kinases: therapeutic potential. Drugs Fut. (2005) 30(1):29-37.
6. MORTLOCK A, KEEN NJ, JUNG FH et al.: Progress in the development of selective inhibitors of Aurora kinases. Curr. Top. In Med. Chem. (2005) 5:199-213.
7. GLOVER DM, LEIBOWITZ MH, MCLEAN DA, PARRY H: Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell (1995) 8(1):95-105.
8. HU HM, CHUANG CK, LEE MJ, TSENG TC, TANG TK: Genomic organization, expression, and chromosome localization of a third aurora-related kinase gene, Aie 1. DNA Cell Biol. (2000) 19(11):679-688.
9. SASAI K, KATAYAMA H, STENOIEN DL et al.: Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil. Cytoskeleton (2004) 59(4):249-263.
10. CARMENA M, EARNSHAW WC: The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. (2003) 4(11):842-854.
11. MARUMOTO T, HONDA S, HARA T et al.: Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J. Biol. Chem. (2003) 278(51):51786-51795.
12. CASTRO A, ARLOT-BONNEMAINS Y, VIGNERON S, LABBE JC, PRIGENT C, LORCA T. APC/fizzy-related targets Aurora-A kinase for proteolysis. EMBO Rep. (2002) 3(5):457-462.
13. HIROTA T, KUNITOKU N, SASAYAMA T et al.: Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell (2003) 114(5):585-598.
14. KUFER TA, SILLJE HH, KORNER R, GRUSS OJ, MERALDI P, NIGG EA: Human TPX2 is required for targeting Aurora-A kinase to the spindle. J. Cell Biol. (2002) 158(4):617-623.
15. BISCHOFF JR, ANDERSON L, ZHU Y et al.: A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J (1998) 17(11):3052-3065.
16. NEBEN K, KORSHUNOV A, BENNER A et al.: Microarray-based screening for molecular markets in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. (2004) 64(9):3103-3111.
17. EWART-TOLAND A, BRIASSOULI P, DE KONING JP et al.: Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibiliry gene in mouse and human. Nat. Genet. (2003) 34(4):403-412.
18. EGAN KM, NEWCOMB PA, AMBROSONE CB et al.: STK15 polymorphism and breast cancer risk in a population-based study. Carcinogenesis (2004) 25(11):2149-2153.
19. MIAO X, SUN T, WANG Y, ZHANG X, TAN W, LIN D: Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res. (2004) 64(8):2680-2683.
20. JENG YM, PENG SY, LIN CY, HSU HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin. Cancer Res. (2004) 10(6):2065-2071.
21. CHEN SS, CHANG PC, CHENG YW, TANG FM, LIN YS: Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J. (2002) 21(17):4491-4499.
22. LIU Q, KANEKO S, YANG L, FELDMAN RI et al.: Aurora-A abrogation ofp53 DNA binding and transactivation activity by phosphorylation of serine 215. J. Biol. Chem. (2004) 279(50):52175-52182.
23. KATAYAMA H, SASAI K, KAWAI H et al.: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. (2004) 36(1):55-62.
24. CARPINELLI P, GIANELLINI L, SONCINI C et al.: Exploring the molecular mechanisms of a small molecule inhibitor of Aurora kinases. 96th Annual AACR Meeting, Anaheim: USA (2005). Astract 663.
25. CASTEDO M, PERFETTINI JL, ROUMIER T, ANDRFAU K, MEDEMA R, KROEMER G: Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 23(16):2825-2837.
26. VOGEL C, KIENITZ A, HOFMANN I, MULLER R, BASTIANS H: Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene (2004) 23(41):6845-6853.
27. EGGERT US, KIGER AA, RICHTER C et al.: Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS. Biol. (2004) 2(12):e379-.
28. HATA T, FURUKAWA T, SUNAMURA M, EGAWA S, MOTOI F, OHMURA N, MARUMOTO T, SAYA H, HORII A: RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. (2005) 65(7):2899-2905.
29. JONKERS J, BERNS A: Oncogene addiction: sometimes a temporary slavery. Cancer Cell (2004) 6(6):535-358.
30. KLEBL B: KinaTor & MasterKey: a chemoproteomics-driven medicinal chemistry approach to kinase inhibitor-based drug development. Protein kinase targets - IBC Conference, Innovations, Opportunities and Real Case Studies, Amsterdam, NE (2004).
31. DITCHFIELD C, JOHNSON VL, TIGHE A et al.: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell. Biol. (2003) 161(2):267-280.
32. MORTLOCK A, KEEN N, JUNG F et al.: Development of a new series of thiazoloquinazoline inhibitors targeting Aurora kinase 95th Annual AACR Meeting. Orlando, USA (2004). Abstract 2480.
33. WILKINSON RW, KEEN N, WEDGE SR et al.: Development and characterization in vivo of an inhibitor with Aurora kinase A and B specificity. 95th Annual AACR Meeting. Orlando, USA (2004). Abstract 842.
34. Vertex inhibitors of Aurora-2, glycogen synthase kinase-3 and Src kinase. Expert Opin. Ther. Patent (2004) 14(3):439-443.
35. GOLEC JMC: Perspectives on the discovery of VX-680, a selective inhibitor of the Aurora kinases. 229th ACS National Meeting. San Diego, USA. (2005). MEDI-307.
36. HARRINGTON EA, BEBBINGTON D, MOORE J et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Medicine (2004) 10(3):262-327.
37. DOGGRELL SA: Dawn of Aurora kinase inhibitors as anticancer drugs. Expert Opin. Investig. Drugs (2004) 13(9):1199-1201.
38. FANCELLI D, BERTA D, BINDI S et al.: al Potent and Selective aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem. (2005) 48(8):3080-3084.
39. HAUF S, COLE RW, LATERRA S et al.: The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. (2003) 161(2):281-294.